Bluebird bio Inc [NASDAQ: BLUE] closed the trading session at $2.94 on 11/01/23. The day’s price range saw the stock hit a low of $2.895, while the highest price level was $3.0675. The company report on October 30, 2023 at 8:00 AM that bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million.
– Non-dilutive capital would strengthen Company’s financial position -.
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV), if received, in connection with the potential approval of lovotibeglogene autotemcel (lovo-cel) for sickle cell disease. Under the terms of the agreement, rights to the PRV will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is contingent upon the U.S. Food and Drug Administration’s (FDA’s) approval of the biologics license application (BLA) for lovo-cel and granting of the PRV.
The stocks have a year to date performance of -57.51 percent and weekly performance of 1.03 percent. The stock has been moved at -27.76 percent over the last six months. The stock has performed -2.33 percent around the most recent 30 days and changed -23.24 percent over the most recent 3-months.
If compared to the average trading volume of 3.54M shares, BLUE reached to a volume of 3659430 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Bluebird bio Inc [BLUE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLUE shares is $7.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLUE stock is a recommendation set at 2.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Bluebird bio Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 17, 2023.
The Average True Range (ATR) for Bluebird bio Inc is set at 0.21, with the Price to Sales ratio for BLUE stock in the period of the last 12 months amounting to 33.45. The Price to Book ratio for the last quarter was 1.08, with the Price to Cash per share for the same quarter was set at 2.31.
BLUE stock trade performance evaluation
Bluebird bio Inc [BLUE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.03. With this latest performance, BLUE shares dropped by -2.33% in over the last four-week period, additionally sinking by -27.76% over the last 6 months – not to mention a drop of -53.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLUE stock in for the last two-week period is set at 48.95, with the RSI for the last a single of trading hit 51.53, and the three-weeks RSI is set at 47.38 for Bluebird bio Inc [BLUE]. The present Moving Average for the last 50 days of trading for this stock 3.19, while it was recorded at 2.90 for the last single week of trading, and 3.96 for the last 200 days.
Bluebird bio Inc [BLUE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bluebird bio Inc [BLUE] shares currently have an operating margin of -10679.79 and a Gross Margin at -319.18. Bluebird bio Inc’s Net Margin is presently recorded at -7411.12.
Return on Total Capital for BLUE is now -81.60, given the latest momentum, and Return on Invested Capital for the company is -61.47. Return on Equity for this stock declined to -93.43, with Return on Assets sitting at -46.41. When it comes to the capital structure of this company, Bluebird bio Inc [BLUE] has a Total Debt to Total Equity ratio set at 143.32. Additionally, BLUE Total Debt to Total Capital is recorded at 58.90, with Total Debt to Total Assets ending up at 50.71. Long-Term Debt to Equity for the company is recorded at 117.26, with the Long-Term Debt to Total Capital now at 48.19.
Reflecting on the efficiency of the workforce at the company, Bluebird bio Inc [BLUE] managed to generate an average of -$825,319 per employee.Bluebird bio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.03 and a Current Ratio set at 2.13.
Earnings per share (EPS) analysis for Bluebird bio Inc [BLUE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLUE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bluebird bio Inc go to 45.80%.
Bluebird bio Inc [BLUE]: Institutional Ownership
The top three institutional holders of BLUE stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in BLUE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in BLUE stock with ownership which is approximately 5.7994%.